HER2-positive breast cancer: cotargeting to overcome treatment resistance
HER2+ breast cancer is an heterogenous disease. Cotargeting HER2 with other signaling
pathways involved in its mechanism of resistance may improve patient outcomes. Research …
pathways involved in its mechanism of resistance may improve patient outcomes. Research …
[HTML][HTML] Palbociclib as an Antitumor Drug: A License to Kill
A Łupicka-Słowik, F Cossu, M Sieńczyk - Molecules, 2024 - mdpi.com
Neoplastic cells are characterized by uncontrolled cell divisions caused by cell cycle
dysregulation. Key regulatory proteins governing the transition from the G1 to the S phase …
dysregulation. Key regulatory proteins governing the transition from the G1 to the S phase …
[HTML][HTML] Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells
S Saharkhiz, N Nasri, N Naderi, G Dini… - International Journal of …, 2024 - Elsevier
In this study, we present a targeted and pH-sensitive niosomal (pHSN) formulation,
incorporating quantum dot (QD)-labeled Trastuzumab (Trz) molecules for the specific …
incorporating quantum dot (QD)-labeled Trastuzumab (Trz) molecules for the specific …
Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
Breast tumors overexpressing human epidermal growth factor receptor (HER2) confer
intrinsic resistance to endocrine therapy (ET), and patients with HER2/estrogen receptor …
intrinsic resistance to endocrine therapy (ET), and patients with HER2/estrogen receptor …
Clinicopathological factors predicting pathological complete response to neoadjuvant anti-HER2 therapy in HER2-positive breast cancer
YJ Jung, S Lee, SK Kang, JY Kim, KS Choo, KJ Nam… - Oncology, 2024 - karger.com
Introduction: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have
shown effectiveness against HER2-positive breast cancer. This makes neoadjuvant …
shown effectiveness against HER2-positive breast cancer. This makes neoadjuvant …